GLP-1
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
Lark's cardiometabolic care coaching programs will be made accessible through CVS Caremark's Point Solutions Management program.
The partnership will give customers easy access to GLP-1 class drugs and other anti-obesity medications.
Two U.S. senators and the Partnership for Safe Medicines sent letters to the FDA, raising concerns that the ad fails to disclose safety and side effect information required in pharmaceutical advertising.
The company says the layoffs occurred due to the need to focus its workforce on critical areas of the business.
The expansion includes prescribing capabilities and entry into the direct-to-consumer market.
The aim is to provide long-term behavioral change focusing on weight loss and maintenance.
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
The company said its drugs will be more accessible than brand-name versions thanks to a partnership with a manufacturer of generic and 503B compounded injectables.
Whole Health Rx will be powered by WellSync, which develops customizable telehealth services for businesses.